JP Patent

JP6334007B2 — ナトリウム（２ｒ，５ｓ，１３ａｒ）−７，９−ジオキソ−１０−（（２，４，６−トリフルオロベンジル）カルバモイル）−２，３，４，５，７，９，１３，１３ａ−オクタヒドロ−２，５−メタノピリド［１’，２’：４，５］ピラジノ［２，１−ｂ］［１，３］オキサゼピン−８−オレート

Assigned to ギリアード サイエンシス インコーポレーテッド · Expires 2018-05-30 · 8y expired

What this patent protects

Patent listed against bictegravir-sodium.

Drugs covered by this patent

Patent Metadata

Patent number
JP6334007B2
Jurisdiction
JP
Classification
—
Expires
2018-05-30
Drug substance claim
No
Drug product claim
No
Assignee
ギリアード サイエンシス インコーポレーテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.